IP Library Granted Patent US 10,273,454
Granted Patent B2
US 10,273,454 · App. 15/612,096 · Granted Apr 30, 2019

Means and methods for influencing the stability of antibody producing cells

Inventors: Hergen Spits (Amsterdam Zuidoost, NL); Ferenc A. Scheeren (Amsterdam, NL); Tim Beaumont (Amsterdam Zuidoost, NL); Sean A. Diehl (Shelburne, VT)
Assignee: ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM
C12N5/0635C07K16/00C12N2501/23C12N2501/231C12N2501/2321C12N2501/52C12N2501/60C12N2502/99C12N2510/02C12N2510/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,273,454
App. No.
15/612,096
Granted
Apr 30, 2019
Kind
B2
Abstract

The invention provides a method for influencing the stability of an antibody producing cell, comprising directly or indirectly influencing the amount of BCL6 and/or Blimp 1 expression product within said antibody producing cell. Stable antibody producing cells and cell lines are also provided, as well as methods for producing antibodies using such cells and/or cell lines.

Claims (8)

1. An antibody producing B cell that is capable of replicating for at least nine weeks, comprising:

an exogenous nucleic acid sequence encoding a peptide comprising Bcl6, or a functional part thereof, capable of increasing the replicative life span of an antibody producing B cell, and

an exogenous anti-apoptotic nucleic acid sequence; wherein the exogenous anti-apoptotic nucleic acid sequence encodes a member of the anti-apoptotic Bcl 2 family.

2. The antibody producing B cell according to claim 1 , wherein the exogenous anti-apoptotic nucleic acid sequence encodes a peptide comprising Bcl-xL, or a functional part thereof capable of increasing the replicative life span of an antibody producing B cell.

3. The antibody producing B cell according to claim 1 , wherein expression of the nucleic acid sequence encoding a peptide comprising Bc16, or a functional part thereof, is regulated by at least one of an activator and/or a repressor that is inducible by an exogenous compound.

4. A B cell culture, comprising antibody producing B cells according to claim 1 .

5. The B cell culture according to claim 4 , wherein the culture further comprises at least one of IL 21 and/or Il 10.

6. The antibody producing B cell according to claim 2 , wherein expression of the nucleic acid sequence encoding a peptide comprising Bcl6, Bcl-xL or a functional part of Bc16 or Bcl-xL, is regulated by at least one of an activator and/or a repressor that is inducible by an exogenous compound.

Assignments (4)
CHANGE OF NAME Recorded Dec 9, 2024
From: ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM
To: STICHTING AMSTERDAM UMC
Reel/Frame 069536/0408 →
CHANGE OF NAME Recorded Sep 11, 2024
From: ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM
To: STICHTING AMSTERDAM UMC
Reel/Frame 071410/0305 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 25, 2021
From: AIMM THERAPEUTICS B.V.
To: KLING BIOTHERAPEUTICS B.V.
Reel/Frame 055711/0534 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 2, 2017
From: SPITS, HERGEN; SCHEEREN, FERENC A.; BEAUMONT, TIM; DIEHL, SEAN A.
To: ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM; AIMM THERAPEUTICS B.V.
Reel/Frame 042674/0210 →
Priority Claims (2)
WO PCT/NL2005/000848 · Dec 9, 2005 · international
EP 06076211 · Jun 12, 2006 · regional
Continuity (3)
Continuation 14836335 · Aug 26, 2015
Division 12086328
Related Publication 20170306293A1 · Oct 26, 2017